Comparison of the Efficacy of Peloid Therapy and Paraffin Treatment in Carpal Tunnel Syndrome

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorBeylikduzu State Hospital

About this trial

This study compares the effectiveness of peloid therapy and paraffin treatment in carpal tunnel syndrome. Patients who have already received 2 weeks of peloid therapy or 15 sessions of paraffin treatment will be assessed. Pain and symptom severity are assessed using the Visual Analog Scale (VAS) and Boston Carpal Tunnel Syndrome Questionnaire (BCTQ). Electrophysiological examinations will also be conducted at the same time points: baseline, 4 weeks post-treatment, and a 12-week follow-up.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients aged between 18 and 65 years old.

Patients diagnosed with mild to moderate carpal tunnel syndrome based on electrophysiological evaluations.

Patients experiencing symptoms for a minimum of 3 months.

Disqualifiers

Patients diagnosed with neuropathic conditions such as polyneuropathy, brachial plexopathy, or thoracic outlet syndrome.

Patients with a history of previous injections or surgery for carpal tunnel syndrome.

Trial population

Patients with mild and moderate carpal tunnel syndrome

Trial design

Design model

Case-control

Time perspective

Other

Treatments tested in this trial

  • No intervention

    Other intervention

    No intervention.

Treatment groups

60 Participants
are divided into 2 treatment groups
Group A: Peloid therapy group1 intervention
Group B: Paraffin treatment group1 intervention

Trial outcomes

Primary outcomes

1

Boston Carpal Tunnel Syndrome Questionnaire

The Boston Carpal Tunnel Syndrome Questionnaire (BCTQ) consists of two parts: the Symptom Severity Scale (SSS) and the Functional Status Scale (FSS). Both parts are scored on a 5-point Likert scale, with higher scores indicating worse symptoms or functional impairment.The highest possible total score for the Symptom Severity Scale is 55, which reflects the most severe symptoms.The highest possible total score for the Functional Status Scale is 40, indicating the greatest functional impairment.The minimum total score is 19 (indicating minimal or no symptoms and functional limitations). The maximum total score is 95 (indicating the most severe symptoms and functional limitations). As the total score increases, the severity of symptoms and functional limitations worsens, meaning higher scores reflect worse outcomes.

Time frame
0 day, 4th week and 12th week

Secondary outcomes

1

Visual Analogue Scale

The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. The Visual Analog Scale (VAS) is a tool used to measure pain intensity. It is typically represented as a 10 cm or 100 mm line, where the patient marks their pain level. The minimum score is 0, which indicates no pain. The maximum score is 100, indicating the worst possible pain. As the score increases, the severity of pain worsens. In this scale, higher scores reflect more intense pain levels. The Visual Analog Scale (VAS) ranges from 0 to 100 where higher scores reflect greater pain intensity.

Time frame
0 day, 4th week and 12th week
2

Median nerve distal motor latency

It is a finding from electrophysiological evaluation

Time frame
0 day, 4th week and 12th week
3

Median nerve distal sensory latency

It is a finding from electrophysiological evaluation

Time frame
0 day, 4th week and 12th week
4

Sensory nerve conduction velocity

It is a finding from electrophysiological evaluation

Time frame
0 day, 4th week and 12th week

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.